Traversa

The recent shooting of University of California, San Diego, researcher and Traversa Therapeutics Co-founder Steven Dowdy allegedly by former Traversa CEO Hans Petersen was prompted by suspicions that Dowdy had been responsible for Petersen's termination and had misappropriated Tr

NEW YORK (GenomeWeb News) – Biotechnology entrepreneur and former Traversa Therapeutics CEO Hans Petersen has been arrested for allegedly shooting University of California, San Diego, researcher and Traversa Co-founder Steven Dowdy, Gene Silencing News has learned.

This article has been updated to clarify details regarding Traversa Therapeutics' bankruptcy proceedings.

Less than a year after Traversa Therapeutics declared bankruptcy, the company's founders are making another run at the RNAi drugs space in the form of startup Solstice Biologics, which announced this week that it has raised $18 million in a Series A round of financing.

The intellectual property ownership dispute between a former Traversa Therapeutics executive and the bankrupt company has been settled, with the executive buying the US patent application at issue, Gene Silencing News has learned.

The former Traversa Therapeutics executive looking to acquire certain of the company's assets as it proceeds through bankruptcy took steps last week to fend off a challenge to his bid for a key patent application, arguing that the one-time employee filing the challenge has no rig

This story has been updated to include comment from a Traversa executive.

Traversa Therapeutics has filed for bankruptcy after failing to secure the financing it needed to continue advancing its core RNAi delivery technology, Gene Silencing News has learned.

Last week, Traversa Therapeutics founder Steve Dowdy presented data at the annual meeting of the American Society of Gene and Cell Therapy in Washington, DC, describing his lab's development of an siRNA cocktail against glioblastoma that incorporates a proprietary delivery technology.

In addition to evaluating RXi's proprietary RNAi compounds, TransDerm will test delivery technologies from Traversa Therapeutics, Thermo Fisher Scientific, and Life Technologies.

Pages

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.